Fig. 3: Inhibition of CCHFV infections by soluble LDLR.
From: Crimean–Congo haemorrhagic fever virus uses LDLR to bind and enter host cells
a, Levels of VSV-CCHF_G infections in human SW13 cells treated with the indicated range of soluble LDLR concentrations or left untreated (mock-treated) (MOI 0.01, 6 h.p.i.). b, Levels of IbAr10200 CCHFV infections in SW13 cells treated with a range of soluble LDLR concentrations (MOI 0.01, 24 h.p.i.). c, Levels of VSV infection in SW13 cells treated with the indicated concentrations of soluble LDLR (MOI 0.01, 6 h.p.i.). d, Levels of RVFV infection of SW13 cells treated with soluble LDLR (MOI 0.01, 24 h.p.i.). e, Levels of IbAr10200 CCHFV infection in SW13 cells treated with soluble VLDLR decoys (MOI 0.01, 24 h.p.i.). f, Levels of VSV infection in SW13 cells treated with soluble VLDLR (MOI 0.01, 6 h.p.i.). Data are mean ± s.d. of n = 3 independent experiments. One-way ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS P > 0.05. Exact P values are available in.
